

4 February 2026

Strong order wins pave way for recovery

Gabriel India's (GABR IN) standalone Q3 revenue grew 15.9% YoY to INR 10.7bn (consolidated revenue up 15.9%). The company expanded its OEM presence by onboarding Hero MotoCorp with one model under development (SOP expected by end of Q1FY27). Consolidated EBITDA margin improved slightly by ~10bps YoY to 9.1% in Q3. Other expenses increased by 24% YoY to INR 1.3bn due to technology support for localization for sunroof, restructuring cost and increase in royalty by ~190bps. Importantly, recent order wins in the sunroof business is encouraging, which was a concern in Q2 and reason behind the sharp share price correction. We reduce our FY26E-27E EPS by 9-10% but maintain Buy with revised TP of INR 1,381.

Robust order wins in 2W and PV to support growth trajectory: GABR continues to build a strong order pipeline with multiple order wins in the 2W and PV segments. In the two-wheeler segment, the company expanded its OEM presence by onboarding Hero MotoCorp with one model under development (SOP expected by end of Q1FY27) along with securing additional inverted fork business from TVS, Bajaj and Kawasaki. In the sunroof segment, GABR won new orders from Hyundai for two new models across three model variants, translating into annual revenues of INR 1.2bn and volumes of 130k units with expected SOP from Dec '27. Additionally, the company secured first development order for upside down front forks for European e-bikes with SOP from Q3FY27. GABR's two-wheeler segment grew 13% in Q3, lagging industry production growth of ~15%, mainly due to: a) higher growth reported by Hero MotoCorp (GABR currently has no presence in Hero, and b) difference in model mix. With the EU-India FTA and US-India trade deals materializing, the export and solar dampener businesses are expected to see a recovery, especially in the US.

Sunroof – FY30-31 revenue target on track: In Q3, the Sunroof segment reported revenues of INR 1.1bn (+16% YoY) with EBITDA margin of 13.5%. A sequential drop in EBITDA margin of 300bps was attributed to additional expenses related to technology, localization support for new business wins and royalty increase by ~190bps. Additionally, GABR aims to improve localization for the sunroof segment to 60% in the next 1.5 years from current 33%. Importantly, the management sounded confident of not only recovering the lost business of Hyundai Creta ICE, by recent order wins but also growing on the same. It is also on track to meet the INR 10bn revenue target for the sunroof business by FY30-31.

Reiterate BUY with a pared TP of INR 1,381: We are encouraged by the announcements for new orders in sunroof business from Hyundai-Kia, which was a concern in Q2 and the key reason behind the sharp fall in share price. Also, the new order wins from HMCL gives visibility of sustained market share in 2Ws. The greatest potential for a re-rating for any auto ancillary company arises from transition from a single- to a multi-product portfolio. As highlighted in our thematic, '[LACE effect 2.0](#)', auto ancillaries have outperformed OEMs in the past decade, on four counts: a) increasing products, b) expansion in segments, c) expansion in geographies and d) inorganic expansion. GABR is a play on all four. That said we lower our FY26E-28E pro forma EPS estimates by 9-10% and thus, revise our TP to INR 1,381 (from INR 1,470) on 40x FY28E EPS, as we roll forward by a quarter. Retain BUY.

Key Financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	34,026	40,634	47,009	57,539	63,892
YoY (%)	-	19.4	15.7	22.4	11.0
EBITDA (INR mn)	2,926	3,897	4,386	5,536	6,447
EBITDA margin (%)	8.6	9.6	9.3	9.6	10.1
Adj PAT (INR mn)	1,787	2,450	2,584	5,159	6,127
YoY (%)	-	37.1	5.5	99.6	18.8
Fully DEPS (INR)	12.4	17.1	18.0	29.1	34.6
RoE (%)	17.8	22.4	20.3	30.7	27.6
RoCE (%)	22.6	27.6	26.4	24.7	22.6
P/E (x)	72.5	52.9	50.1	31.0	26.1
EV/EBITDA (x)	44.2	33.2	29.5	23.4	20.1

Note: Pricing as on 03 February 2026; Source: Company, Elara Securities Estimate

Rating: Buy

Target Price: INR 1,381

Upside: 53%

CMP: INR 902


As on 03 February 2026

Key data

Bloomberg	GABR IN
Reuters Code	GABR.NS
Shares outstanding (mn)	144
Market cap (INR bn/USD mn)	130/1,436
EV (INR bn/USD mn)	129/1,434
ADTV 3M (INR mn/USD mn)	579/6
52 week high/low	1,388/436
Free float (%)	44

Note: as on 03 February 2026; Source: Bloomberg

Price chart



Source: Bloomberg

	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Shareholding (%)				
Promoter	55.0	55.0	55.0	55.0
% Pledge	0.0	0.0	0.0	0.0
FII	5.2	6.0	6.5	6.5
DII	14.6	15.0	15.7	16.2
Others	25.2	24.0	22.8	22.3

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(0.1)	4.7	10.1
Gabriel India	(29.9)	(10.0)	85.0
NSE Mid-cap	(1.0)	4.2	11.0
NSE Small-cap	(8.4)	(5.3)	1.8

Source: Bloomberg


Jay Kale, CFA

Auto Ancillaries, Automobiles

+91 22 6164 8507
jay.kale@elaracapital.com

Associates
Munindra Upadhyay
munindra.upadhyay@elaracapital.com

Neel Doshi
neel.doshi@elaracapital.com



Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	34,026	40,634	47,009	57,539	63,892
Gross Profit	8,509	10,524	12,319	15,248	16,931
EBITDA	2,926	3,897	4,386	5,536	6,447
EBIT	2,327	3,084	3,395	4,339	5,327
Interest expense	82	102	136	300	270
Other income	194	260	250	300	315
Exceptional/ Extra-ordinary items	-	-	-	-	-
PBT	2,438	3,242	3,509	4,339	5,372
Tax	651	792	791	1,096	1,357
Minority interest/Associates income	-	-	(133)	1,915	2,111
Reported PAT	1,787	2,450	2,584	5,159	6,127
Adjusted PAT	1,787	2,450	2,584	5,159	6,127
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	10,022	11,833	13,642	19,064	23,352
Minority Interest	-	-	-	893	1,080
Trade Payables	5,877	6,262	7,128	8,111	7,720
Provisions & Other Current Liabilities	1,511	1,804	2,002	2,343	2,565
Total Borrowings	252	239	-	1,518	1,218
Other long term liabilities	-	-	-	-	-
Total liabilities & equity	17,662	20,137	22,772	31,928	35,934
Net Fixed Assets	5,926	7,108	7,956	8,698	9,537
Goodwill	-	-	-	-	-
Intangible assets	-	-	-	-	-
Business Investments / other NC assets	894	299	949	6,892	7,542
Cash, Bank Balances & treasury investments	765	394	416	388	1,323
Inventories	3,015	3,639	4,182	5,098	5,661
Sundry Debtors	4,914	6,002	6,440	7,882	8,752
Other Current Assets	2,147	2,694	2,829	2,971	3,119
Total Assets	17,662	20,137	22,772	31,928	35,934
Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Cashflow from Operations	1,766	2,038	3,524	5,179	5,495
Capital expenditure	(1,628)	(2,086)	(1,800)	(1,899)	(1,917)
Acquisitions / divestitures	(1,027)	642	(650)	(5,942)	(650)
Other Business cashflow	1,368	(44)	-	-	-
Free Cash Flow	138	(48)	1,724	3,280	3,579
Cashflow from Financing	285	(920)	(1,053)	2,634	(1,993)
Net Change in Cash / treasury investments	765	(370)	22	(28)	935
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	4.0	3.0	5.4	8.7	10.4
Book value per share (INR)	69.8	82.4	95.0	107.6	131.8
RoCE (Pre-tax) (%)	22.6	27.6	26.4	24.7	22.6
ROIC (Pre-tax) (%)	24.5	29.1	27.3	25.3	23.5
ROE (%)	17.8	22.4	20.3	30.7	27.6
Asset Turnover (x)	5.7	6.2	6.2	6.9	7.0
Net Debt to Equity (x)	(0.1)	0.0	0.0	0.1	0.0
Net Debt to EBITDA (x)	(0.2)	0.0	(0.1)	0.2	0.0
Interest cover (x) (EBITDA/ int exp)	35.5	38.3	32.3	18.5	23.9
Total Working capital days (WC/rev)	37.0	45.6	39.5	41.1	51.5
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	72.5	52.9	50.1	31.0	26.1
P/Sales (x)	3.8	3.2	2.8	2.3	2.0
EV/ EBITDA (x)	44.2	33.2	29.5	23.4	20.1
EV/ OCF (x)	73.3	63.5	36.7	25.0	23.6
FCF Yield	0.1	0.0	1.3	2.5	2.8
Price to BV (x)	12.9	11.0	9.5	8.4	6.8
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0

Note: Pricing as on 03 February 2026; Source: Company, Elara Securities Estimate

Exhibit 1: Consolidated Q3FY26 financials

Particulars (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	QoQ (%)
Revenue	11,787	10,166	15.9	11,803	(0.1)	12,059	(2.3)
Operating costs	10,718	9,251	15.9	10,675	0.4	10,935	(2.0)
EBITDA	1,069	915	16.8	1,128	(5.3)	1,124	(4.9)
EBITDA margin (%)	9.1	9.0	7	9.6	(49.2)	9.3	(25.5)
Depn & amort.	255	194	31.2	251	1.7	250	1.9
EBIT	814	721	13.0	878	(7.3)	874	(6.9)
Interest expense	32	30	7.0	28	12.9	30	6.7
Other Income	70	95	(25.5)	61	16.0	70	0.6
Pretax profit	852	785	8.5	910	(6.3)	914	(6.8)
Tax	173	184	(6.3)	220	(21.5)	219	(21.3)
Tax rate (%)	20.2	23.5		24.2	(390.7)	24.0	(374.3)
Adjusted Net profit	680	601	13.1	690	(1.5)	695	(2.2)
Exceptionals	(133)						
Reported Net Profit	547	601	(9.1)	690	(20.8)	695	(21.3)
EPS (INR)	5	4	13.1	5	(1.5)	5	(2.2)

Source: Company, Elara Securities Estimate

Exhibit 2: Standalone Q3FY26 financial performance

Particulars (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Variance (%) /bp
Revenue	10,716	9,242	15.9	10,661	0.5	10,905	(1.7)
Operating costs	9,792	8,458	15.8	9,738	0.6	9,978	(1.9)
EBITDA	924	784	17.8	923	0.1	927	(0.4)
EBITDA margin (%)	8.6	8.5	14	8.7	(4)	8.5	12.0
Depn & amort.	195	156	24.7	190	2.5	190	2.6
EBIT	729	628	16.1	733	(0.5)	737	(1.1)
Interest expense	21	14	53.0	12	69.9	15	38.6
Other Income	235	94	151.0	92	155.0	100	135.2
Pretax profit	943	708	33.3	813	16.1	822	14.7
Tax	157	168	(6.7)	206	(24.0)	205	(23.7)
Tax rate (%)	16.6	23.7		25.4	(874.8)	25.0	(837.6)
Adjusted Net profit	786	540	45.7	607	29.7	616	27.6
Exceptionals	(130)	0		0		0	
Reported Net Profit	656	540	21.6	607	8.2	616	6.5
EPS (INR)	5.5	3.8	45.7	4.2	29.7	4.3	27.6

Source: Company, Elara Securities Estimate

Q3 conference call takeaways

- ▶ **Business wins:**
 - ▶ **Two-wheeler:** GABR made inroads into Hero Motor Corporation and secured additional business wins on inverted front forks with multiple customers (TVS, Bajaj, Kawasaki).
 - ▶ **e-bike:** GABR received first development orders from a customer in Europe for an upside-down front fork.
 - ▶ **Solar damper development** is progressing well, and the samples have been submitted for validation to two customers, with feedback awaited. Two more developments are in progress.
 - ▶ **Sunroof:** GABR won new business with Hyundai for 2 models (three variants), in addition to existing models under development with Kia and Hyundai.
- ▶ **Inalfa Gabriel Sunroof Systems Pvt (IGSS):** Revenue from operations in Q3 stood at INR 1.1bn with EBITDA margins at 13.5%.

- ▶ Hyundai Sunroof order: GABR won orders for three model variants, with expected volumes of 130k and annual turnover of INR 1.2bn. SOP is expected by Dec '27. With three new variant wins, GABR is seeking 60-70% utilization on the second line moving forward. Further refresh of the *Syros* model is expected around March/April, which should improve utilization.
- ▶ Hero order win: One model is currently under development with SOP expected by end of Q1FY27.
- ▶ Other expense increased 24% YoY to INR 1.3bn, mainly due to: a) technology support on localization, design and development and sunroof, and b) restructuring cost.
- ▶ The share of two-wheeler segment dropped (61% versus 65% in Q2) due to Motherson Maraelli numbers (primarily PV, CV) coming into play, increasing the PV/CV portfolio.
- ▶ E-bike Forks
 - ▶ GABR secured first order win for an upside-down front fork for an e-bike in Europe.
 - ▶ Development orders are being released. SOP is expected in Q3FY27. Other businesses are under discussion.
- ▶ Utilization of FTAs (India-EU, US-India):
 - ▶ India-Europe FTA will enhance technology support through the tech center and improve competitiveness due to duty changes (compensating transportation costs). GABR is already receiving interest from European customers.
 - ▶ North America: GABR is optimistic about solar dampers due to India-US trade deal, as North America is a big market for solar dampeners, which were impacted due to the tariffs.
- ▶ Capacity utilization
 - ▶ Two-wheeler capacity: GABR is continuously adding capacity, in line with market growth and new business wins (e.g., Hero Motocorp). Current two-wheeler capacity is ~70% during normal demand periods, allowing for idle capacity to meet festival season demand.
 - ▶ Localization target: GABR will target 60% localization for sunroofs by end of FY26-27 (next 1.5 years).

Exhibit 3: Earnings revision

Earnings	Earlier			Current			% change		
INR mn	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Consolidated									
Revenues	47,264	61,377	67,306	47,009	57,539	63,892	(0.5)	(6.3)	(5.1)
EBITDA	4,498	6,240	7,308	4,386	5,536	6,447	(2.5)	(11.3)	(11.8)
EBITDA margin	9.5	10.2	10.9	9.3	9.6	10.1	(19)	(54)	(77)
PAT	2,778	5,758	6,762	2,584	5,159	6,127	(7.0)	(10.4)	(9.4)
EPS	19.3	32.5	38.2	18.0	29.1	34.6	(7.0)	(10.4)	(9.4)
Target price (INR)	1,470			1,381			(6.0)		


Source: Elara Securities Estimate

Exhibit 4: Valuation summary

(INR)	FY28E
Pro forma EPS	34.6
P/E multiple	40
Target price (INR)	1381

Source: Elara Securities Estimate

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
01-Jul-2024	Buy	624	481
22-Oct-2024	Buy	647	419
30-Jan-2025	Buy	666	452
01-Jul-2025	Buy	1,115	843
30-Jul-2025	Buy	1,336	1,050
13-Nov-2025	Buy	1,470	1,230
03-Feb-2026	Buy	1,381	902

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/and> Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India
Elara Securities (India) Private Limited
 One International Center, Tower 3,
 21st Floor, Senapati Bapat Marg,
 Elphinstone Road (West)
 Mumbai – 400 013, India
 Tel : +91 22 6164 8500

Europe
Elara Capital Plc.
 6th Floor, The Grove,
 248A Marylebone Road,
 London, NW1 6JZ,
 United Kingdom
 Tel : +44 20 7486 9733

USA
Elara Securities Inc.
 230 Park Avenue, Suite 2415,
 New York, NY 10169, USA
 Tel: +1 212 430 5870
 Fax: +1 212 208 2501

Asia / Pacific
Elara Capital (Asia) Pte.Ltd.
 One Marina Boulevard,
 Level 20,
 Singapore 018989
 Tel : +65 6978 4047



**Managing
Director**

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of
Research**

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &
Australia**

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate
Access,
Conference &
Events**

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#).

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
 Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
 Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509